{"id":9471,"date":"2023-06-01T21:01:17","date_gmt":"2023-06-01T21:01:17","guid":{"rendered":"https:\/\/www.yuhan-usa.com\/?p=9471"},"modified":"2023-06-02T18:45:51","modified_gmt":"2023-06-02T18:45:51","slug":"yuhan-makes-325m-cancer-bet-to-challenge-boehringer-takeda","status":"publish","type":"post","link":"https:\/\/www.yuhan-usa.com\/yuhan-makes-325m-cancer-bet-to-challenge-boehringer-takeda\/","title":{"rendered":"Yuhan makes $325M cancer bet to challenge Boehringer, Takeda"},"content":{"rendered":"\n<p>Yuhan Corporation has bought its way into a cancer space targeted by Boehringer Ingelheim and Takeda,&nbsp;<a href=\"https:\/\/www.prnewswire.com\/news-releases\/yuhan-corporation-and-j-ints-bio-inked-a-licensing-agreement-for-a-new-drug-candidate-targeting-her2-nsclc-301838147.html\" rel=\"noreferrer noopener\" target=\"_blank\">wagering<\/a>&nbsp;up to $325 million to get its hands on a preclinical HER2 tyrosine kinase inhibitor (TKI).<\/p>\n\n\n\n<p>The oral drug candidate, which Korea\u2019s Yuhan is licensing from its compatriot J INTS BIO, is designed for use in non-small cell lung cancer (NSCLC) patients with HER2 exon 20 insertion mutations. Around 3% of NSCLC patients have HER2 mutations, and around 90% of those mutations are exon 20 insertions. The potential to improve outcomes in that subset of patients has attracted a clutch of drug developers.&nbsp;<\/p>\n\n\n\n<p>Spectrum Pharmaceuticals sought FDA approval for poziotinib in NSCLC harboring HER2 exon 20 insertion mutations late in 2021 but&nbsp;<a href=\"https:\/\/investor.sppirx.com\/news-releases\/news-release-details\/spectrum-pharmaceuticals-receives-complete-response-letter-us\">deprioritized<\/a>&nbsp;the program after receiving a rejection notice last year. Rival drug candidates remain in active clinical development, with Boehringer&nbsp;<a href=\"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04886804\">studying<\/a>&nbsp;BI 1810631 in a phase 1 trial and Takeda securing approval two years ago for&nbsp;mobocertinib, a TKI that targets EGFR and HER2 insertions.&nbsp;<\/p>\n\n\n\n<p>Flanked by deep-pocketed rivals with more advanced programs, J INTS BIO has&nbsp;<a href=\"https:\/\/aacrjournals.org\/cancerres\/article\/83\/7_Supplement\/4029\/724689\">pitched<\/a>&nbsp;its TKI candidate as a potential best-in-class molecule. The claim, which is backed by in vitro and in vivo models showing it is potent against HER2 exon 20 insertions, has helped the Korean biotech land a deal for the therapy.<\/p>\n\n\n\n<p>Yuhan has taken the other side of the agreement. The Korean drugmaker, which owns a 15% stake in J INTS BIO, is paying $1.9 million upfront as part of a deal worth up to $325 million to secure rights to the JIN-A04 drug candidate.&nbsp;&nbsp;&nbsp;<\/p>\n\n\n\n<p>At Yuhan, JIN-A04 will slot into a pipeline led by the EGFR TKI lazertinib. Johnson &amp; Johnson&nbsp;<a href=\"https:\/\/www.fiercebiotech.com\/biotech\/janssen-taps-south-korea-s-yuhan-for-tagrisso-rival\">paid<\/a>&nbsp;Yuhan $50 million upfront and committed to $1.2 billion in milestones for rights to the small molecule outside of Korea in 2018. Yuhan went on to launch the drug in Korea, under the Leclaza name, as a second-line treatment for NSCLC while continuing to study the molecule in other settings.&nbsp;<br><br>Link to original article: <a href=\"https:\/\/www.fiercebiotech.com\/biotech\/yuhan-makes-325m-cancer-bet-challenge-boehringer-takeda\" target=\"_blank\" rel=\"noreferrer noopener\">https:\/\/www.fiercebiotech.com\/biotech\/yuhan-makes-325m-cancer-bet-challenge-boehringer-takeda <\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Yuhan Corporation has bought its way into a cancer space targeted by Boehringer Ingelheim and Takeda,&nbsp;wagering&nbsp;up to $325 million to get its hands on a preclinical HER2 tyrosine kinase inhibitor (TKI). The oral drug candidate, which Korea\u2019s Yuhan is licensing from its compatriot J INTS BIO, is designed for use in non-small cell lung cancer [&hellip;]<\/p>\n","protected":false},"author":3,"featured_media":9473,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":[],"categories":[56],"tags":[53,52],"_links":{"self":[{"href":"https:\/\/www.yuhan-usa.com\/wp-json\/wp\/v2\/posts\/9471"}],"collection":[{"href":"https:\/\/www.yuhan-usa.com\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.yuhan-usa.com\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.yuhan-usa.com\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/www.yuhan-usa.com\/wp-json\/wp\/v2\/comments?post=9471"}],"version-history":[{"count":3,"href":"https:\/\/www.yuhan-usa.com\/wp-json\/wp\/v2\/posts\/9471\/revisions"}],"predecessor-version":[{"id":9478,"href":"https:\/\/www.yuhan-usa.com\/wp-json\/wp\/v2\/posts\/9471\/revisions\/9478"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.yuhan-usa.com\/wp-json\/wp\/v2\/media\/9473"}],"wp:attachment":[{"href":"https:\/\/www.yuhan-usa.com\/wp-json\/wp\/v2\/media?parent=9471"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.yuhan-usa.com\/wp-json\/wp\/v2\/categories?post=9471"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.yuhan-usa.com\/wp-json\/wp\/v2\/tags?post=9471"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}